Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study
BackgroundRecurrent angina, which is defined as a return of chest pain or chest discomfort, occurs in many patients undergoing coronary interventions. ObjectiveThis study aims to compare the antianginal efficacy of ranolazine versus allopurinol for eligible sympto...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2022-08-01
|
| Series: | Interactive Journal of Medical Research |
| Online Access: | https://www.i-jmr.org/2022/2/e39778 |
| _version_ | 1797734801587830784 |
|---|---|
| author | Reza Rahmani Ehsan Moradi Farsani Sima Bahrami |
| author_facet | Reza Rahmani Ehsan Moradi Farsani Sima Bahrami |
| author_sort | Reza Rahmani |
| collection | DOAJ |
| description |
BackgroundRecurrent angina, which is defined as a return of chest pain or chest discomfort, occurs in many patients undergoing coronary interventions.
ObjectiveThis study aims to compare the antianginal efficacy of ranolazine versus allopurinol for eligible symptomatic patients with a history of angioplasty.
MethodsA total of 62 eligible symptomatic patients with a history of angioplasty were randomly allocated into two groups. For group A, 300 mg of allopurinol was administered twice daily, while for group B, 1000 mg of ranolazine daily was prescribed for a duration of 4 weeks. An initial screening visit was done for all participants where patients’ medical history was recorded and a physical examination was given; electrocardiography, blood pressure, and heart rate measurements were done as well. The patients were also given a blood and exercise test. At the end of the medication period, participants were revisited, and the tests were done again. All the required data were collected via a researcher-made form, and data analysis was conducted using SPSS. The study was approved by a formal ethics committee.
ResultsThe mean age of participants in the two groups (A and B) was 57.36 (SD 8.36) and 60.27 (SD 9.17) years, respectively. Among the 62 patients, 34 (59%) were men, while 28 (41%) were women. Creatinine, fasting blood sugar, C-reactive protein, N-terminal prohormone of brain natriuretic protein, uric acid, white blood cell, and hemoglobin levels of participants were not significantly different between groups (P>.05). Both allopurinol and ranolazine increased the total exercise time and decreased the ST depression of the patients. Additionally, they both improved the chest pain severity and Duke Treadmill Score of patients. At the same time, ranolazine had a statistically greater effect on ST depression reduction (mean 2.64, SD 0.74 vs mean 1.57, SD 0.49), while allopurinol showed better efficacy in reducing chest pain severity (mean 1.86, SD 0.37 vs mean 0.59, SD 0.21) and the Duke Treadmill Score (mean –14.77, SD 3.65 vs mean –6.88, SD 1.93).
ConclusionsBased on the results, the antianginal efficacy of allopurinol and ranolazine was approved but with different effects on ST depression, chest pain severity, and the Duke Treadmill Score. Therefore, the precise differences in their effects need to be explored further. |
| first_indexed | 2024-03-12T12:49:43Z |
| format | Article |
| id | doaj.art-95882c2852494415af7343bd938e4d18 |
| institution | Directory Open Access Journal |
| issn | 1929-073X |
| language | English |
| last_indexed | 2024-03-12T12:49:43Z |
| publishDate | 2022-08-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | Interactive Journal of Medical Research |
| spelling | doaj.art-95882c2852494415af7343bd938e4d182023-08-28T22:53:53ZengJMIR PublicationsInteractive Journal of Medical Research1929-073X2022-08-01112e3977810.2196/39778Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy StudyReza Rahmanihttps://orcid.org/0000-0001-8828-0825Ehsan Moradi Farsanihttps://orcid.org/0000-0001-7746-7352Sima Bahramihttps://orcid.org/0000-0002-4634-2992 BackgroundRecurrent angina, which is defined as a return of chest pain or chest discomfort, occurs in many patients undergoing coronary interventions. ObjectiveThis study aims to compare the antianginal efficacy of ranolazine versus allopurinol for eligible symptomatic patients with a history of angioplasty. MethodsA total of 62 eligible symptomatic patients with a history of angioplasty were randomly allocated into two groups. For group A, 300 mg of allopurinol was administered twice daily, while for group B, 1000 mg of ranolazine daily was prescribed for a duration of 4 weeks. An initial screening visit was done for all participants where patients’ medical history was recorded and a physical examination was given; electrocardiography, blood pressure, and heart rate measurements were done as well. The patients were also given a blood and exercise test. At the end of the medication period, participants were revisited, and the tests were done again. All the required data were collected via a researcher-made form, and data analysis was conducted using SPSS. The study was approved by a formal ethics committee. ResultsThe mean age of participants in the two groups (A and B) was 57.36 (SD 8.36) and 60.27 (SD 9.17) years, respectively. Among the 62 patients, 34 (59%) were men, while 28 (41%) were women. Creatinine, fasting blood sugar, C-reactive protein, N-terminal prohormone of brain natriuretic protein, uric acid, white blood cell, and hemoglobin levels of participants were not significantly different between groups (P>.05). Both allopurinol and ranolazine increased the total exercise time and decreased the ST depression of the patients. Additionally, they both improved the chest pain severity and Duke Treadmill Score of patients. At the same time, ranolazine had a statistically greater effect on ST depression reduction (mean 2.64, SD 0.74 vs mean 1.57, SD 0.49), while allopurinol showed better efficacy in reducing chest pain severity (mean 1.86, SD 0.37 vs mean 0.59, SD 0.21) and the Duke Treadmill Score (mean –14.77, SD 3.65 vs mean –6.88, SD 1.93). ConclusionsBased on the results, the antianginal efficacy of allopurinol and ranolazine was approved but with different effects on ST depression, chest pain severity, and the Duke Treadmill Score. Therefore, the precise differences in their effects need to be explored further.https://www.i-jmr.org/2022/2/e39778 |
| spellingShingle | Reza Rahmani Ehsan Moradi Farsani Sima Bahrami Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study Interactive Journal of Medical Research |
| title | Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study |
| title_full | Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study |
| title_fullStr | Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study |
| title_full_unstemmed | Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study |
| title_short | Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study |
| title_sort | ranolazine versus allopurinol for eligible symptomatic patients with a history of angioplasty comparative efficacy study |
| url | https://www.i-jmr.org/2022/2/e39778 |
| work_keys_str_mv | AT rezarahmani ranolazineversusallopurinolforeligiblesymptomaticpatientswithahistoryofangioplastycomparativeefficacystudy AT ehsanmoradifarsani ranolazineversusallopurinolforeligiblesymptomaticpatientswithahistoryofangioplastycomparativeefficacystudy AT simabahrami ranolazineversusallopurinolforeligiblesymptomaticpatientswithahistoryofangioplastycomparativeefficacystudy |